Vasopressin analogue DDAVP in diabetes insipidus: clinical and laboratory studies.
In seven patients with cranial diabetes insipidus an analogue of vasopressin, DDAVP, produced an antidiuresis lasting up to 20 hours after a single intranasal dose. Lysine vasopressin (LVP) in the same dose produced a less potent antidiuresis which lasted for only three to four hours. The plasma half life of DDAVP was 7.8 and 75.5 min for the fast and slow phases, compared with 2.5 and 14.5 min for LVP. Radioiodine-labelled DDAVP was not destroyed by incubation with late pregnancy plasma, which contains an enzyme that inactivates vasopressin. The slow metabolic clearance of DDAVP, its absorption through the nasal mucosa, and its lack of side effects make this the ideal drug for the treatment of vasopressin-sensitive diabetes insipidus. Patients usually require 10 to 20 mug DDAVP given intranasally twice daily for good clinical control of their diabetes insipidus.
D000293:Adolescent; D000328:Adult; D000906:Antibodies; D001769:Blood; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003919:Diabetes Insipidus / Q000188:drug therapy*; D004231:Diuresis / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D007456:Iodine Isotopes; D008875:Middle Aged; D009297:Nasal Mucosa; D009666:Nose; D009994:Osmolar Concentration; D011485:Protein Binding; D014556:Urine; D014667:Vasopressins / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*
D000906:Antibodies; D007456:Iodine Isotopes; D014667:Vasopressins